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The non-competitive NMDA receptor (NMDA-R) antagonist phencyclidine (PCP)Fused as a pharmacological model of
schizophreniaFdisrupts prefrontal cortex (PFC) activity. PCP markedly increased the discharge rate of pyramidal neurons and reduced
slow cortical oscillations (SCO; 0.15–4 Hz) in rat PFC. Both effects were reversed by classical (haloperidol) and atypical (clozapine)
antipsychotic drugs. Here we extended these observations to mice brain and examined the potential involvement of 5-HT2A and 5-HT1A
receptors (5-HT2AR and 5-HT1AR, respectively) in the reversal by clozapine of PCP actions. Clozapine shows high in vitro affinity for
5-HT2AR and behaves as partial agonist in vivo at 5-HT1AR. We used wild-type (WT) mice and 5-HT1AR and 5-HT2AR knockout mice
of the same background (C57BL/6) (KO-1A and KO-2A, respectively). Local field potentials (LFPs) were recorded in the PFC of WT,
KO-1A, and KO-2A mice. PCP (10 mg/kg, intraperitoneally) reduced SCO equally in WT, KO-2A, and KO-1A mice (58±4%, 42±7%,
and 63±7% of pre-drug values, n¼ 23, 13, 11, respectively; po0.0003). Clozapine (0.5 mg/kg, intraperitoneally) significantly reversed
PCP effect in WT and KO-2A mice, but not in KO-1A mice nor in WT mice pretreated with the selective 5-HT1AR antagonist
WAY-100635.The PCP-induced disorganization of PFC activity does not appear to depend on serotonergic function. However, the lack
of effect of clozapine in KO-1A mice and the prevention by WAY-100635 indicates that its therapeutic action involves 5-HT1AR
activation without the need to block 5-HT2AR, as observed with clozapine-induced cortical dopamine release.
Neuropsychopharmacology (2012) 37, 723–733; doi:10.1038/npp.2011.249; published online 19 October 2011
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INTRODUCTION
The prefrontal cortex (PFC) plays a fundamental role in
higher brain functions (Fuster, 1997; Miller and Cohen,
2001). Numerous observations suggest an abnormal func-
tion of this cortical area in schizophrenia (Elvevag and
Goldberg, 2000; Goldman-Rakic, 1994; Lewis and Anderson,
1995; Uhlhaas and Singer, 2010; Uhlhaas and Singer, 2006;
Winterer et al, 2004). In particular, anatomical, cellular, and
neurochemical alterations have been reported in the frontal
lobe of patients with schizophrenia (Harrison, 1999; Lewis
and Lieberman, 2000; Lewis et al, 2005; Selemon and
Goldman-Rakic, 1999).
Non-competitive NMDA receptor (NMDA-R) antagonists
such as phencyclidine (PCP) or ketamine exacerbate clinical
symptoms in patients with schizophrenia and induce
behavioral alterations that resemble schizophrenia symp-
toms in healthy individuals and experimental animals
(Handelmann et al, 1987; Hudzik and Wenger, 1993;
Jentsch and Roth, 1999; Krystal et al, 1994; Krystal et al,
2003; Pradhan, 1984; Stefani and Moghaddam, 2005; Verma
and Moghaddam, 1996). In particular, acute PCP adminis-
tration to humans induces a schizophrenia-like state (Allen
and Young, 1978; Bakker and Amini, 1961; Castellani et al,
1982; Javitt and Zukin, 1991; Luby et al, 1959; Steinpreis,
1996). Overall, these observations have led to the use of
these agents as pharmacological models of schizophrenia
(Javitt and Zukin, 1991; Krystal et al, 1994; Malhotra et al,
1997; Newcomer et al, 1999). Clozapine (CLZ) the prototype
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of atypical antipsychotic drugs attenuates the behavioral
and cognitive impairments induced by the acute adminis-
tration of non-competitive NMDA-R antagonists (Geyer
et al, 2001; Idris et al, 2005; Lipina et al, 2005).
Previous results indicate that acute PCP administration
induces a profound loss of cortical synchrony at low
frequencies (slow cortical oscillations, SCO; 0.15–4 Hz), an
effect reversed by the subsequent administration of classical
(haloperidol) and atypical (CLZ) antipsychotic drugs
(Kargieman et al, 2007). PCP also exerts similar alterations
in thalamic nuclei interconnected with the PFC, which are
also reversed by CLZ administration (Santana et al, 2011).
Interestingly, the hallucinogen DOI, a preferential 5-HT2A
receptor (5-HT2AR) agonist, induced a comparable loss of
SCO in PFC, an effect also reversed by haloperidol and CLZ
(Celada et al, 2008). Overall, these observations suggest that
the reduction in SCO and its reversal by antipsychotic drugs
may be a useful model to identify new targets in
antipsychotic drug development.
5-HT1A receptor (5-HT1AR) and 5-HT2AR are abundantly
expressed in rodent PFC (Pompeiano et al, 1992, 1994;
Santana et al, 2004), where they are mostly co-expressed
(Amargos-Bosch et al, 2004). They mediate opposing
actions (inhibitionsF5-HT1AR; excitationsF5-HT2AR) of
5-HT and selective agonists (Amargos-Bosch et al, 2004;
Araneda and Andrade, 1991; Marek and Aghajanian, 1999;
Puig et al, 2005). CLZ shows an affinity for 5-HT2AR greater
than that for dopamine D2 receptors (Meltzer, 1999).
Likewise, despite showing moderate in vitro affinity for
5-HT1AR, CLZ and other atypical antipsychotic drugs
behave as agonists at 5-HT1AR in vivo to increase PFC
dopamine release (Bortolozzi et al, 2010; Diaz-Mataix et al,
2005; Ichikawa et al, 2001; Rollema et al, 1997).
In this study, we examined whether PCP also alters SCO
in mouse PFC. Moreover, taking advantage of the avail-
ability of mice lacking 5-HT1AR and 5-HT2AR, we further
examined the involvement of such serotonin (5-HT) recep-
tors in the mechanism of action of PCP and CLZ in the
above-mentioned effects on SCO.
MATERIALS AND METHODS
Animals and Treatments
C57BL/6 (wild-type, WT) mice were used. Male homo-
zygous 5-HT1AR knockout (hereafter referred as KO-1A)
mice and male homozygous 5-HT2A receptor knockout mice
(hereafter referred as KO-2A) were also used. Both strains
were on a C57/BL6 background. Generation of both
KO strains has been reported elsewhere (Fiorica-Howells
et al, 2002; Parks et al, 1998; Weisstaub et al, 2006). From
these initial sources, mice were transferred to the animal
facility of the University of Barcelona School of Medicine,
where stable colonies were grown. Animals were kept in a
controlled environment (12 h light–dark cycle and 22±2 1C
room temperature) with food and water provided ad
libitum. Animal care followed the European Union regula-
tions (OJ of EC L358/1 18/12/1986) and was approved by the
Institutional Animal Care and Use Committee.
PCP and CLZ were from Sigma/RBI (Natick, MA). Doses
are expressed as free bases. Mice were injected intraperi-
toneally with the following treatments: (a) PCP (10 mg/kg),
followed by CLZ (0.5 mg/kg); (b) PCP (10 mg/kg), followed
by saline; and (c) saline, followed by CLZ (0.5 mg/kg). Time
between injections was 10–12 min. The dose of CLZ was
chosen from the literature owing to its ability to antagonize
behavioral effects of NMDA-R antagonists (Bradford et al,
2010; Gleason and Shannon, 1997; Mutlu et al, 2011; Scorza
et al, 2010; Yadav et al, 2011).
To further evaluate the role of the 5-HT1AR on CLZ-
induced reversal of PCP actions on PFC, we performed an
additional experiment in which mice were pretreated with
saline or the selective 5-HT1AR antagonist WAY-100635
(0.3 mg/kg, subcutaneously) 30 min before CLZ administra-
tion, as used previously (Duvvuri et al, 2009).
At the end of the experiments, mice were killed by
anesthetic overdose and the placement of recording
electrodes verified histologically.
Local Field Potential Recordings
We examined drug effects on local field potential (LFP). LFP
recordings provide a measure of population neuronal
activity around the tip of the recording electrode (Schroeder
and Lakatos, 2009; Shoham and Nagarajan, 2003) and allow
to assess oscillatory electrical activity.
Mice were anesthetized with chloral hydrate (400 mg/kg,
intraperitoneally) and positioned in a David Kopf stereo-
taxic frame. Additional doses of chloral hydrate (40 mg/kg)
were administered intraperitoneally. Body temperature was
maintained at 37 1C with a heating pad. LFPs were recorded
with glass micropipettes pulled from 2 mm capillary glass
(World Precision Instruments, Sarasota, FL) on a Narishige
(Tokyo, Japan) PE-2 pipette puller. The electrode imped-
ance was between 4 and 8 MO. The signal was amplified
( 10) with a Neurodata IR283 (Cygnus Technology,
Delaware Water Gap, PA), post-amplified ( 100) and
filtered using a band-pass filter (0.1–100 Hz) (Cibertec
amplifier/filter, Madrid, Spain), and computed online using
a DAT 1401plus interface system Spike2 software (CED).
Descents in the medial PFC (mPFC) were carried out at
AP + 2.2 to + 2.4, L 0.2 to 0.4, and DV 1.0 to 2.5
below brain surface. Stereotaxic coordinates were taken
from bregma and duramater according to the mouse brain
atlas (Franklin and Paxinos, 1997). After recording stable
baseline activity for 5 min, PCP (10 mg/kg in saline) was
slowly (15 s) administered intraperitoneally. CLZ (0.5 mg/kg,
intraperitoneally) was injected 10 min after PCP admini-
stration. At the end of experiments, mice were killed by an
overdose of anesthetic.
Data Analysis
The effect of PCP was examined in WT (n¼ 23), KO-1A
(n¼ 11), and KO-2A (n¼ 13) mice. Off-line analysis was
performed using the SPIKE 2 software (Cambridge Elec-
tronic Design, Cambridge, UK). Power spectra were
constructed by using fast Fourier transformation of 1-min
signal intervals (band-pass filter of 0.1–100 Hz) correspond-
ing to baseline, PCP, and PCP + CLZ. Power resolution was
0.15 Hz. Analyses of drug effects on SCO (0.15–4 Hz) and on
the dominant wave (B1 Hz) of SCO were measured
separately. Results are given as AUCs.
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In addition, we measured the number of active phases
in LFP recordings using a script of the Spike2 software.
As observed in Figure 1a in basal conditions, the discharge
of PFC pyramidal neurons occurs only during the active
phase of the LFP, corresponding to depolarized or ‘UP’
states recorded intracellularly (Steriade et al, 1993a,b). Each
downward deflection in the LFP trace was considered an
active (or UP) phase when the time between two adjacent
events was 4250 ms (eg, o4 Hz; upper limit of SCO), and
the amplitude of the deflection was three times the ampli-
tude of the inactive phase. The actual recordings, as well as
the number of active (UP) phases, transcribed as events, are
shown in Figure 1a.
The power spectra and the number of active phases were
analyzed in 1-min time periods corresponding to baseline
conditions (immediately before PCP administration),
after PCP (10 min post-administration), and PCP + CLZ
(10 min after CLZ administration). These time windows
were selected on the basis of the behavioral effects of
intraperitoneal administration of PCP, which start 3–4 min
after injection and last for more than 20 min, as observed in
non-anesthetized mice. Drug effects were analyzed using
ANOVA, followed by post-hoc t-tests (Newman–Keuls) or
paired Student’s t-test, as appropriate. Statistical signifi-
cance was set at the 95% confidence level (two-tailed). Data
are given as means±SEM.
RESULTS
Characteristics of SCO in Mouse mPFC
LFP recordings of mouse mPFC in baseline conditions
show the presence of characteristic SCO (0.15–4 Hz) with
a marked predominance of a sharp wave at B1 Hz
(Figure 1). As observed in other species (Kargieman et al,
2007; Mukovski et al, 2007; Steriade et al, 1993b), action
potentials were discharged in temporal coincidence with
active phases of LFP (Figure 1a). Individual differences
in SCO and in the B1 Hz oscillations were paralleled by
changes in the number of active phases. Significant corre-
lations were found between the basal values of these
variables: (i) SCO (0.15–4 Hz) vs 1 Hz oscillation (r¼ 0.99;
po0.0001); (ii) SCO (0.15–4 Hz) vs number of active (UP)
phases (r¼ 0.82; po0.0001); and (iii) 1 Hz oscillation vs
number of active (UP) phases (r¼ 0.81; po0.0001) (n¼ 31;
Figure 1). The high correlation between the individual
values of SCO and the 1 Hz oscillation indicates that the
latter wave is the main contribution to SCO in mice PFC.
The power spectra of SCO did not differ between
genotypes (WT: 0.024±0.003; KO-1A: 0.016±0.003; and
KO-2A: 0.017±0.004 mV2; (F(2, 44)¼ 1.67, p¼ 0.20), n¼ 23,
11, and 13, respectively). Likewise, the power spectra of the
1 Hz oscillation (WT: 0.018±0.002; KO-1A: 0.011±0.002;
and KO-2A: 0.012±0.003 mV2; n¼ 23, 11, and 13, respec-
tively) and the number of active phases per min (WT:
25.83±1.81; KO-1A: 22.9±3.31; and KO-2A: 18.54±2.68;
n¼ 23, 11, and 13, respectively) did not significantly differ
among genotypes (F(2, 44)¼ 2.55, p¼ 0.09) and (F(2, 44)¼
2.44, p¼ 0.1) for 1 Hz oscillation and the number of active
phases per minute, respectively. The three variables (power
spectra of SCO andB1 Hz wave as well as number of active
phases) were equally sensitive to drug effects (see below).
Effect of PCP on mPFC Oscillations
As previously reported in rats (Kargieman et al, 2007), the
systemic administration of PCP to WT mice reduced SCO,
from 0.024±0.003 to 0.013±0.002 mV2 (58.4±4.1% of
baseline; po0.00001; paired Student’s t-test, n¼ 23). This
reduction was paralleled by a similar decrease in the
number of actives phases (from 25.8±1.8 to 14.1±1.1;
54.6% of baseline; po0.000001, Student’s t-test, n¼ 23).
Figure 2 shows a representative example of the effect of PCP
Figure 1 (a) Lower trace and mid-trace show action potential recorded
extracellularly and local field potential (LFP) in mouse prefrontal cortex
(PFC) in basal conditions. The upper trace depicts the number of UP states
(see Materials and methods). Time bar is 5 s. (b) Power spectrum of the
example is shown in (a). Note the predominance of the oscillation close to
1 Hz. (c–e) Correlations found between the individual basal values of three
variables used in this study, (c) shows the correlation between the area
under the curves (AUCs) of the power spectra of the 1 Hz oscillation
(abscissa) with that of slow cortical oscillations (SCO) (0.15–4 Hz)
(ordinate) (r¼ 0.99; n¼ 31). (d and e) show, respectively, the correlations
between the AUCs of SCO and of the 1 Hz oscillation (abscissa) with the
number of UP states (ordinate) (r¼ 0.82 and 0.81, respectively; n¼ 31).
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on SCO as well as the average effects on power spectra and
number of active phases.
To examine the kinetics of PCP effect on SCO in mice,
we measured the effect of PCP at 10 and 20 min post-
administration in six experiments. Changes in PFC activity
started at approximately 4 min after intraperitoneal admin-
istration of PCP and persisted for at least 20 min (Figures 2
and 3). One-way repeated-measures ANOVA of the power
spectra of SCO revealed a significant effect of PCP at 10 and
20 min after administration (0.025±0.007, 0.017±0.006,
and 0.012±0.004mV2 in basal conditions and 10 and 20 min
after PCP, respectively ((F(2, 10)¼ 9.47, po0.005), n¼ 6),
with no significant differences between 10 and 20 min
(Figures 2a and 3). Similarly, there were no differences
between the number of active phases at 10 and 20 min
(22.8±3.3, 13.5±3.3, and 12.7±3.3) events per min in basal
conditions and after 10 and 20 min of PCP administration,
respectively ((F(2, 10)¼ 18.56, po0.0004), n¼ 6; Figure 3).
Saline injections did not alter SCO, 1 Hz oscillations, nor
the number of active phases (data not shown). Also, saline
injections did not modify the SCO suppression induced
by the subsequent PCP administration (Figure 2).
Effect of PCP on mPFC Oscillations in KO-1A and
KO-2A Mice
Systemic PCP administration reduced SCO (0.15–4 Hz)
similarly in the mPFC of WT, KO-1A, and KO-2A mice
(Figures 2 and 4). Two-way ANOVA revealed a significant
effect of PCP ((F(1, 44)¼ 50.00, po0.0001), n¼ 23, 11, and
13 for WT, KO-1A, and KO-2A mice, respectively), with no
significant effects of genotype and treatment genotype
interaction.
The analyses of the effect of PCP on the 1 Hz oscillation
also revealed a reduction of the power spectra in all geno-
types. Two-way ANOVA revealed a significant effect of PCP
((F(1, 44)¼ 38.87, po0.0001), n¼ 23, 11, and 13 for WT,
KO-1A, and KO-2A mice, respectively), with no significant
effects of genotype and treatment genotype interaction.
As in WT mice, PCP administration also reduced the
number of active phases in the mPFC of KO-1A and KO-2A
mice, from 22.9±3.3 to 13.2±2.8 events per min (KO-1A,
po0.001; Student’s t-test, n¼ 11) and from 18.54±2.68
to 7.85±1.13 events per min (KO-2A, po0.001; Student’s
t-test, n¼ 13). Two-way ANOVA revealed a significant
effect of PCP ((F(1, 44)¼ 126.05, po0.0001), n¼ 23, 13,
and 11 for WT, KO-2A and KO-1A mice, respectively) and
genotype (F(2, 44)¼ 3.51, po0.05), but no significant effect
of treatment genotype interaction (Figure 4).
CLZ Reversal of PCP Effect
Next, we next examined whether (i) CLZ could reverse PCP
effects on SCO in the PFC of WT mice, as observed in rats
(Kargieman et al, 2007), and (ii) whether CLZ effects were
comparable in all genotypes (WT, KO-1A, and KO-2A).
WT Mice
As observed in rats (Kargieman et al, 2008), CLZ (0.5 mg/kg,
intraperitoneally) had no effect by itself on SCO in WT mice
(113% of basal values; NS, n¼ 4).
In the WT mice treated with PCP + CLZ (n¼ 19), PCP
reduced SCO to 59.9±4.4% of baseline, an effect signifi-
cantly reversed by CLZ administration (Figure 5). One-way
repeated-measures ANOVA revealed a significant effect of
treatment (F(2, 36)¼ 30.82; po0.00001), with significant
post-hoc differences between PCP vs baseline and PCP +
CLZ vs PCP, indicating that CLZ reversed PCP effects on
SCO in mouse PFC.
When the effects of PCP and CLZ were assessed by the
change of the B1 Hz wave or the number of active phases,
the results were similar. Thus, PCP reduced the B1 Hz
wave to 55.4±4.7% of baseline, an effect reversed by CLZ
((F(2, 36)¼ 35.22; po0.00001), n¼ 19; one-way repeated-
measures ANOVA), with significant post-hoc differences
between PCP vs baseline and PCP + CLZ vs PCP (Figure 5).
Likewise, CLZ reversed the PCP-evoked reduction in the
number of active phases ((F(2, 36)¼ 22.11; po0.00001),
n¼ 19; one-way ANOVA), with significant post-hoc differ-
ences between PCP vs baseline and PCP + CLZ vs PCP
(Figure 5).
Figure 2 Effect of phencyclidine (PCP) administration on slow cortical oscillations (SCO). (a) Local field potential (LFP) recording and power spectra of a
representative experiment showing the decrease in SCO after PCP administration. Small bars below the LFP recording denote the one 1-min period
corresponding to the power spectrums shown below. Note that PCP effect persisted for at least 25 min. (b) Spectrograms showing the effects of the
administration of PCP and saline in the time periods shown in (a). Time bar in abscissa are 10 s; ordinates are in Hz. The intensity of the power spectrum is
color-coded (red¼ high intensity; blue¼ low intensity). (c) Bar graph showing the effects of PCP on SCO, and on the number of active phases per minute.
*po0.00001 vs baseline; n¼ 23.
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Genotype Comparisons
As observed in WT mice, the administration of CLZ
(0.5 mg/kg, intraperitoneally) significantly reversed PCP
effects on SCO in KO-2A mice, but failed to do it in KO-1A
mice (Figure 6). Two-way ANOVA (treatment, geno-
type) analysis of the SCO data in all genotypes revealed
a significant effect of treatment (F(2, 78)¼ 39.9, po0.0001)
and significant treatment genotype interaction ((F(4, 78)¼
13.09, po0.00001), n¼ 19, 11, and 12 for WT, KO-1A, and
KO-2A mice, respectively). Post-hoc comparisons showed
significant differences between PCP vs baseline activity in
all genotypes and significant post-hoc differences between
PCP + CLZ treatment vs treatment with PCP alone in
WT mice and in KO-2A mice, but not in KO-1A mice
(Figure 6).
Likewise, on the number of active phases, two-way
ANOVA revealed a significant effect of treatment (F(2, 78)¼
71.07, po0.0001), genotype (F(2, 39)¼ 9.13 po0.001),
and treatment genotype interaction ((F(4, 78)¼ 15.29;
po0.00001), n¼ 19, 11, and 12 for WT, KO-1A, and KO-
2A mice, respectively), with significant post-hoc differences
between PCP vs baseline in all genotypes and significant
post-hoc differences between PCP + CLZ vs PCP in WT mice
and in KO-2A mice. On the contrary, post-hoc comparisons
showed that CLZ administration did not significantly
reverse the effect of PCP in KO-1A mice (Figure 6). So,
CLZ significantly overturned PCP effect in WT and KO-2A
mice, but not in KO-1A mice.
Prevention of CLZ Effect in WT Mice by the 5-HT1AR
Antagonist WAY-100635
Pretreatment with the 5-HT1AR antagonist WAY-100635
(0.3 mg/kg, subcutaneously) prevented the CLZ reversal of
PCP-evoked reduction on SCO without having any effect on
SCO by itself. Two-way ANOVA revealed a significant effect
of treatment (F(3, 30)¼ 23.76, po0.001) and of the treat-
ment pretreatment interaction ((F(3, 30)¼ 3.88, po0.02),
n¼ 6 for saline and WAY-100635 pretreatment, respec-
tively), with significant post-hoc differences between PCP vs
baseline in both groups. Likewise, Newman–Keuls post-hoc
test revealed a significant difference in the effect of CLZ
in saline and WAY-100635-pretreated mice (Figure 7).
Likewise, two-way ANOVA also revealed a significant
effect of treatment (F(3, 30)¼ 8.54, po0.0003) and treat-
ment pretreatment interaction (F(3, 30)¼ 5.02; po0.01)
(n¼ 6 each group) on the number of active phases. As
observed with power spectra, Newman–Keuls post-hoc test
revealed a significant difference in the effect of CLZ in saline
and WAY-100635-pretreated mice (Figure 6).
DISCUSSION
This study shows that PCP is able to alter SCO in mouse
PFC, thus extending previous observations in rat PFC,
indicating a general action of PCP on rodent brain. This
allows the use of transgenic mice to examine the involve-
ment of neurotransmitter receptors in drug effects. In this
regard, an important and novel observation of this study
is the requirement of 5-HT1AR activation for the CLZ-
mediated reversal of PCP effects on SCO, indicating that
5-HT1AR play an important role in the therapeutic action of
CLZ. Likewise, a new methodological contribution of this
study is the use of the number of active (UP) phases as a
new variable to examine drug effects on cortical synchrony.
These findings are consistent with previous reports of the
effects of psychotomimetic agents (eg, PCP and DOI) on
SCO in rat PFC (Celada et al, 2008; Kargieman et al, 2007)
and thalamic nuclei projecting to PFC (Santana et al, 2011).
Hence, PCP markedly alters SCO in the PFC of both rodent
species (Kargieman et al, 2007; this study) and these effects
are restored by classical (haloperidol) and atypical (CLZ)
antipsychotic drugs (Kargieman et al, 2007).
Cortical neurons exhibit synchronous, hyperpolarized
(resting or DOWN state), and plateau depolarized (UP
state) membrane potential fluctuations during slow-wave
Figure 3 Bar graphs showing the effects of phencyclidine (PCP) on slow
cortical oscillations (SCO) (a), on the B1 Hz oscillation (b), and on the
number of active phases per minute (c) 10 and 20 min after administration.
*po0.05, **po0.005 vs basal.
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sleep and in anesthetized animals (Steriade et al, 1993a,b;
Lewis and O’Donnell, 2000; Mukovski et al, 2007). These
changes can be observed at the population level as SCO in
LFP and EEG recordings (Destexhe et al, 2007; Steriade
et al, 1993b). The B1-Hz cortical oscillation, predominant
in SCO, appears to be essential for information processing
in PFC (Engel et al, 2001; Engel and Singer, 2001). Hence,
boosting low EEG frequencies during sleep has been shown
to improve memory (Marshall et al, 2006), and the
disruption of cortical network synchrony may have a
negative impact on working memory and in behavioral
representation, two important PFC-dependent tasks altered
in schizophrenia (Elvevag and Goldberg, 2000).
The study of cortical oscillatory activity has a high
translational value for the study of the pathophysiology and
treatment of schizophrenia, as well as in the identification
of neurobiological targets for drug development (Ford
et al, 2007). Although most neurophysiological studies
assessing oscillatory activity in schizophrenic patients have
focused on high-frequency oscillations (b, g) (Kwon et al,
1999; Spencer et al, 2003; Uhlhaas and Singer, 2006),
alterations in lower frequencies have also been reported
(Basar-Eroglu et al, 2009; Shin et al, 2010), which may be
relevant to the emergence of schizophrenia symptoms given
Figure 4 Effect of phencyclidine (PCP) on slow cortical oscillations (SCO) in the prefrontal cortex (PFC) of 5-HT2A receptor (5-HT2AR)- and 5-HT1AR-
knockout (KO) mice (KO-2A and KO-1A, respectively). Representative effect of PCP on SCO in the PFC of a KO-2A mouse (a) and a KO-1A mouse (c).
Power spectrum show a decrease of SCO (0.15–4 Hz) after intraperitoneal (i.p.) PCP administration. Bar graph shows the effect of PCP on SCO and on the
number of active phases per minute in KO-2A mice (b) and KO-1A mice (d). *po0.002; n¼ 13 and 11, respectively.
Figure 5 Reversal by clozapine (CLZ) of the phencyclidine (PCP)-
induced reduction in slow cortical oscillations (SCO), B1 Hz cortical
oscillations, and number of active per minute. *po0.0002 vs basal,
#po0.01 vs PCP, and ##po0.0005 vs PCP.
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the involvement of slow oscillations in cognitive processes
and memory consolidation (Stickgold, 2005; Marshall et al,
2006).
Here we report that PCP administration markedly
reduced synchrony in mouse PFC, as assessed by SCO
(0.15–4 Hz), 1-Hz oscillations, and the number of active
phases. These variables are correlated since they all reflect
the synchronized alternating activity states of neuronal
populations in the recording area and were equally sensitive
to drug effects.
In normal conditions, action potentials are discharged
synchronically in temporal coincidence with active (UP)
phases (Kargieman et al, 2007; Mukovski et al, 2007;
Steriade et al, 1993b; Figure 1), yet in the presence of PCP,
cortical synchrony is markedly reduced or lost, whereas
discharge rate is enhanced, leading to a profound temporal
disorganization of PFC neuronal activity (Kargieman et al,
2007; this study).
The reduction of SCO and number of active phases is
possibly due to an imbalance between excitatory and
inhibitory neurotransmission within the PFC. In the rat
PFC, PCP markedly increased (B3-fold) the discharge
rate of a 45% of pyramidal neurons and reduced it in
another 33% (Kargieman et al, 2007). UP states are
sustained by a balance of excitatory and inhibitory network
interactionsFincluding afferent modulatory inputsFand
by intrinsic cellular mechanisms (Contreras and Steriade,
1995; Lewis and O’Donnell, 2000; O’Donnell and Grace,
1995; Sanchez-Vives and McCormick, 2000; Shu et al,
2003; Timofeev et al, 2000a, 2000b). Hence, the decrease
in GABAergic activity reported in the NMDA-R model
of schizophrenia (Gonzalez-Burgos and Lewis, 2008;
Homayoun and Moghaddam, 2007; Krystal et al, 2003;
Lewis et al, 2005) may account for this effect, assuming
a preferential blockade of NMDA-R in GABAergic inter-
neurons by PCP. Thus, the blockade of GABAA-mediated
inhibitions with picrotoxin decreased the number of UP
states (Cossart et al, 2003) and suppressed slow-wave
oscillations (Shu et al, 2003). In support of this view, PCP
mainly induced the expression of c-fosFa marker of
neuronal activityFin cortical pyramidal neurons and on
excitatory thalamic neurons, but not in GABA interneurons
in PFC and subcortical areas reciprocally connected with
PFC (Kargieman et al, 2007; Santana et al, 2011).
Overall, the present and past observations (Kargieman
et al, 2007; Santana et al, 2011) indicate that PCP evokes a
highly disorganized state in PFC, with an increased pyra-
midal discharge occurring in a random manner, without the
temporal frame of theB1 Hz oscillation, an effect occurring
also in thalamic neurons reciprocally connected with PFC
(Santana et al, 2011). This pattern of action is similar to that
observed in recent human neuroimaging studies with
ketamine (Vollenweider and Kometer, 2010). Given the
top–down control exerted by PFC on most cortical and
subcortical areas (Miller and Cohen, 2001), the disruption
of PFC and thalamic function by PCP may have a profound
impact on a large number of brain functions, which may
account for the perceptual, cognitive, affective, and motor
actions of PCP (Krystal et al, 1994, 2003).
PCP increases 5-HT release in PFC (Amargos-Bosch et al,
2006) and endogenous 5-HT can excite or inhibit pyramidal
cell activity via 5-HT2AR and 5-HT1AR, respectively
(Araneda and Andrade, 1991; Puig et al, 2005). The similar
effects of PCP in all genotypes indicate that changes in SCO
Figure 6 Reversal by clozapine of phencyclidine (PCP) effects on cortical oscillation in the three genotypes. (a) Graphs showing the average effects of PCP
and PCP + clozapine (CLZ) as assessed by the area under the curves (AUCs) of power spectra (upper graph) and the number of active phases (lower
graph). Note the lack of CLZ reversal in knockout (KO)-1A mice. n¼ 23, 11, and 12 for wild-type (WT), KO-1A, and KO-2A mice. *po0.001 vs basal;
#po0.05 vs PCP; ##po0.0005 vs PCP; apo0.0002, a‘po0.01 post-hoc test after two-way analysis of variance (ANOVA) (see text). (b) Representative
examples of the power spectra of slow cortical oscillations (SCO) in mice prefrontal cortex (PFC) obtained in basal conditions, after PCP and after the
subsequent CLZ administration (10 and 20 min after PCP administration, respectively) in the three genotypes. Note the marked reduction of the power of
SCO in the three genotypes by PCP and the reversal induced by CLZ in WT and KO-2A mice, but not in KO-1A mice.
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occur upstream of the change in 5-HT release and without a
significant involvement of such receptor populations.
In contrast, the effect of CLZ markedly differs among
mouse genotypes. As in rat PFC, CLZ reversed PCP effect on
SCO in WT and KO-2A mice. However, CLZ was without
effect in KO-1A mice. Previous studies have demonstrated
varying in vitro affinities of CLZ for 5-HT1AR, for which it
behaves as a partial agonist. Hence, CLZ displays a modest
affinity for 5-HT1AR (B100 nM) (Kroeze et al, 2003; Roth
et al, 2004), whereas affinities in the range 700–800 nM were
reported previously (Arnt and Skarsfeldt, 1998; Bymaster
et al, 1996). Despite this moderate–low in vitro affinity,
CLZ exerts a number of its in vivo pharmacological
actionsFparticularly the increase in PFC DA releaseFvia
5-HT1AR activation (Bortolozzi et al, 2010; Diaz-Mataix
et al, 2005; Ichikawa et al, 2001; Rollema et al, 1997), an
observation that may have several interpretations.
5-HT1AR and 5-HT2AR are highly co-expressed in rat and
mouse PFC neurons (Amargos-Bosch et al, 2004). Thus,
although there are no compensatory changes of other 5-HT
receptors in KO-1A and KO-2A mice (Amargos-Bosch et al,
2004; Bortolozzi et al, 2010; Popa et al, 2005), the blockade
of 5-HT2AR by CLZ might alter the physiological balance
between 5-HT1AR and 5-HT2AR, resulting in an increase
of 5-HT1AR-mediated neurotransmission. However, these
results, obtained in anesthetized mice, together with a
recent report on the effect of CLZ on dopamine release in
the PFC of awake mice (Bortolozzi et al, 2010) do not
support this view, as CLZ reversed the effects of PCP on
SCO in KO-2A mice, whereas it did not in KO-1A mice.
Moreover, the observation that WAY-100635 pretreatment
prevented the CLZ-induced reversal of PCP effects on
SCO suggests a direct interaction of CLZ (or its main
metabolite N-desmethylclozapine) with 5-HT1AR. This view
agrees with PET scan data, indicating the partial displace-
ment of [11C]WAY-100635 (a hardly displaceable ligand)
by CLZ in monkey brain (Chou et al, 2003). This apparent
discrepancy between in vitro and in vivo data may be also
accounted for by the contribution of the main CLZ
metabolite, N-desmethylclozapine, which shows 5-HT1AR
affinity in the 10 nM range (http://www.kidb.case.edu/
pdsp.php).
Figure 7 The 5-HT1A receptor (5-HT1AR) antagonist WAY-100635 prevents the clozapine (CLZ) reversal of phencyclidine (PCP) effect on slow cortical
oscillations (SCO) in wild-type (WT) mice. (a) Representative examples of local field potential (LFP) recording in prefrontal cortex (PFC) from mice
pretreated with saline (a1) and WAY-100635 (0.3 mg/kg, subcutaneously) (a2). Spectrograms showing the effects of the administration of WAY-100635 or
saline, PCP, and CLZ in the time periods shown in the upper scheme. The intensity of the power spectrum is color-coded (red¼ high intensity; blue¼ low
intensity) (b and c) Bar graph showing the prevention by WAY-100635 (0.3 mg/kg, subcutaneously) pretreatment of CLZ reversal of PCP-evoked reduction
on SCO (b) and on the number of active phases per minute (c). WAY-100635 by itself has not effect on both parameters. *po0.02 vs basal, #po0.01
saline-PCP-CLZ vs WAY-100635-PCP-CLZ.
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The requirement of 5-HT1AR activation by CLZ to restore
SCO is entirely similar to its ability to enhance PFC dopamine
release, an effect thought to be involved in the superior
efficacy of CLZ on negative symptoms and cognitive deficits
(Leucht et al, 2009a, b). Hence, CLZ and other atypical
antipsychotic drugs (but not classical dopamine D2 blockers)
share the ability to increase DA release in rodent mPFC
through 5-HT1AR activation (Bortolozzi et al, 2007; Diaz-
Mataix et al, 2005; Ichikawa et al, 2001; Li et al, 2009; Rollema
et al, 1997, 2000), an effect depending on the exclusive
activation of 5-HT1AR in mPFC as observed in KO mice
(Bortolozzi et al, 2007, 2010; Diaz-Mataix et al, 2005). These
results also agree with a recent report indicating that CLZ’s
ability to normalize NMDA-R hypofunction in vivo depends
on an intact presynaptic serotonergic function and that
5-HT2AR are not essential for CLZ reversal of PCP-induced
disruption of sensory–motor gating (Yadav et al, 2011).
Irrespectively of the mechanisms involved, the require-
ment of 5-HT1AR for CLZ to increase dopamine release in
PFC and to restore SCO suggests an association between both
effects that requires further investigation. Hence, the
dopamine increase may restore the loss of SCO via activation
of D1 receptors in fast-spiking interneurons (Tseng et al,
2006). In support of the involvement of GABA interneurons
in the effect of CLZ, the combination of PCP and CLZ
induced the expression of c-fos in PFC GABAergic neurons
(Kargieman et al, 2007; Santana et al, 2011), suggesting that
CLZ may restore cortical synchrony via an enhancement of
GABA inputs onto pyramidal neurons excited by PCP.
In summary, this study shows for the first time that PCP
markedly reduces cortical synchrony in mouse PFC. The
experiments carried out in KO mice illustrate the validity of
this model to examine the involvement of neurotransmitter
receptors in drug effects and indicate that the actions of
CLZ to restore cortical synchrony require the presence of
5-HT1AR, as observed using other experimental models,
such as the cortical release of dopamine (Bortolozzi et al,
2010). Overall, this adds further support to the involve-
ment of this 5-HT receptor in antipsychotic drug action
(Newman-Tancredi, 2010).
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